H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on TScan Therapeutics (TCRX) to $10 from $15 and keeps a Buy rating on the shares. The firm lowered its valuation multiples and increased the stock’s discount rates to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCRX:
- TScan Therapeutics Reports Q1 2025 Financial Results
- Positive Outlook for TScan Therapeutics: Buy Rating Backed by Strong Financials and Promising Clinical Developments
- TScan Therapeutics reports Q1 EPS (26c), consensus (28c)
- TScan Therapeutics appoints Camiolo as SVP, Market Access
- TScan Therapeutics assumed with an Overweight at Morgan Stanley